Is neuroglial antigen 2 a potential contributor to cilengitide response in glioblastoma?
JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, cilt.13, sa.2, ss.329-336, 2017 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 13 Sayı: 2
- Basım Tarihi: 2017
- Doi Numarası: 10.4103/0973-1482.188438
- Dergi Adı: JOURNAL OF CANCER RESEARCH AND THERAPEUTICS
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
- Sayfa Sayıları: ss.329-336
- Anahtar Kelimeler: Apoptosis, cell detachment, dose-response relationship, drug resistance, gene expression, PHASE-II TRIAL, NEWLY-DIAGNOSED GLIOBLASTOMA, RECURRENT MALIGNANT GLIOMAS, NG2 PROTEOGLYCAN, ENDOTHELIAL-CELLS, TEMOZOLOMIDE, BEVACIZUMAB, PHOSPHORYLATION, ALPHA-V-BETA-3, ACTIVATION
- Recep Tayyip Erdoğan Üniversitesi Adresli: Evet
Özet
Background: Determining the expression levels of neuroglial antigen 2 (NG2) in glioma cell lines and to evaluate the potential contribution of NG2 to cilengitide response were aimed.